Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Research & Development (2022 - 2025)

CervoMed's Research & Development history spans 5 years, with the latest figure at $6.0 million for Q3 2025.

  • For Q3 2025, Research & Development rose 17.86% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $23.1 million, up 58.39%, while the annual FY2024 figure was $18.8 million, 122.77% up from the prior year.
  • Research & Development for Q3 2025 was $6.0 million at CervoMed, up from $5.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $7.1 million in Q4 2024 and bottomed at $380685.0 in Q4 2022.
  • The 4-year median for Research & Development is $2.8 million (2023), against an average of $3.4 million.
  • The largest YoY upside for Research & Development was 650.06% in 2023 against a maximum downside of 24.43% in 2023.
  • A 4-year view of Research & Development shows it stood at $380685.0 in 2022, then surged by 650.06% to $2.9 million in 2023, then soared by 148.19% to $7.1 million in 2024, then decreased by 14.76% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Research & Development are $6.0 million (Q3 2025), $5.1 million (Q2 2025), and $4.8 million (Q1 2025).